Patents by Inventor Florian KOEHLER

Florian KOEHLER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides displayed by HLA for use in immunotherapy against different types of cancers
    Patent number: 12290530
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: May 6, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • Peptides displayed by HLA for use immunotherapy against different types of cancers
    Patent number: 12285443
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: April 29, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • Peptides displayed by HLA for use immunotherapy against different types of cancers
    Patent number: 12274716
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: April 15, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • Peptides displayed by HLA for use in immunotherapy against different types of cancers
    Patent number: 12257269
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: March 25, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • Peptides displayed by HLA for use in immunotherapy against different types of cancers
    Patent number: 12246039
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 23, 2024
    Date of Patent: March 11, 2025
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240374642
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: November 14, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240374640
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: November 14, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240366669
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: November 7, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240358757
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: October 31, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240358755
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 31, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240358756
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: October 31, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • Core-Shell Nanodisc Synthesis and Applications to Single-Particle Targeted Magnetothermal Control of Biological Signaling
    Publication number: 20240347239
    Abstract: Anisotropic magnetothermal nanoparticles and methods for making the same are disclosed. The anisotropic magnetothermal nanoparticle may include a core and a shell. The core may include hexagonal nanodisc hematite (Fe2O3). The shell may include AxFe3-xO4, where A=Co, Mn, Ni, Fe, Zn, Mg, or Cu. The anisotropic magnetothermal nanoparticle may also include a polymer coating.
    Type: Application
    Filed: April 15, 2024
    Publication date: October 17, 2024
    Inventors: Polina Olegovna ANIKEEVA, Ye Ji Kim, Florian Koehler
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240307447
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: September 19, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240299455
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 8, 2024
    Publication date: September 12, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240269183
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: August 15, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240269184
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 15, 2024
    Publication date: August 15, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240245723
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 23, 2024
    Publication date: July 25, 2024
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE
  • Peptides displayed by HLA for use in immunotherapy against different types of cancers
    Patent number: 11957716
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: April 16, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20220226376
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 21, 2022
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE